New hope for PNH patients: drug shows promise in early trial
Disease control
Completed
This study tested a new drug called OMS906 in 12 adults with PNH, a rare blood disease, who were not getting enough benefit from the standard treatment ravulizumab. The goal was to see if OMS906 is safe and can raise hemoglobin levels. Participants received OMS906 every 8 weeks, …
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated May 17, 2026 11:34 UTC